钠-葡萄糖共转运蛋白2抑制剂致非高血糖性酮症酸中毒研究进展  

Research progress in euglycemic diabetic ketoacidosis induced by sodium-glucose transporter 2 inhibitors

作　　者：杨晓德 谢晓竞[1] Yang Xiaode;Xie Xiaojing(Department of Endocrinology,Nanjing Hospital Affiliated to Nanjing Medical University(Nanjing First Hospital),Nanjing 210006,China)

机构地区：[1]南京医科大学附属南京医院(南京市第一医院)内分泌科,江苏南京210006

出　　处：《实用药物与临床》2022年第10期925-928,共4页Practical Pharmacy and Clinical Remedies

基　　金：南京市医学科技发展项目(YKK17107)。

摘　　要：钠-葡萄糖共转运蛋白2抑制剂(SGLT2i)通过抑制近端小管的葡萄糖重吸收,增加尿糖排泄来降低血糖水平,并且具有心血管、肾脏保护作用,已经逐渐成为二线降糖药物。随着应用人群的不断扩大,其非高血糖性酮症酸中毒(euDKA)的副作用报道逐渐增加,因患者血糖通常正常或稍高于正常值,不易引起医生及患者注意,易误诊。因此,本文主要就SGLT2i导致euDKA的相关机制及诱因、预防措施进行综述,为降低此类药物在临床上的不良风险提供依据。Sodium-glucose cotransporter 2 inhibitors(SGLT2 i) reduce blood glucose levels by inhibiting glucose re-absorption in proximal tubules and increasing urine glucose excretion,and they have cardiovascular and renal protective effects,gradually becoming second-line hypoglycemic drugs.With the continuous expansion of the application population,reports on the side effects of euglycemic ketoacidosis(euDKA) are gradually increasing,and because patients′ blood glucose is usually normal or slightly higher than normal,it is not easy to attract the attention of doctors and patients,so it is easy to lead to misdiagnosis.Therefore,this paper mainly reviews the related mechanisms,predisposing factors and preventive measures of euDKA induced by SGLT2 i,in order to provide evidence for reducing the clinical adverse risks of these drugs.

关 键 词：钠-葡萄糖共转运蛋白2(SGLT2)抑制剂 非高血糖性酮症酸中毒 药物不良反应 

分 类 号：R969[医药卫生—药理学]